Insights on Paroxynase 1 and Therapeutic Preferences in Rheumatoid Arthritis

This chapter examines a study from ACR Convergence 2024 that identifies paroxynase 1 as a potential biomarker for predicting the progression to inflammatory arthritis in anti-CCP positive patients. The discussion also includes insights on therapy preferences and the clinical implications of these findings.

Transcript

Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!

Get the app